Introduction
RCC is the 12th most common cancer worldwide and the third leading cause of mortality amongst genitourinary malignancies, representing a significant health burden [1] . Despite the increase of incidental carcinomas detected on radiological imaging,~25% of patients with RCC present with metastases at the time of diagnosis [2] . Furthermore, between 20% and 40% of patients undergoing nephrectomy for localised RCC will develop metastatic disease [3] . Historically, patients with disseminated disease had a dismal prognosis with an estimated 5-year survival rate of <5% and median survival times of 6-10 months [4] . Over the last decade with the advent of novel targeted therapies 5-year survival rates have increased modestly to 8% [1].
In the pre-targeted therapy era, evidence based on two significant prospective randomised trials confirmed the role of cytoreductive nephrectomy (CN) in the management of metastatic RCC (mRCC) in conjunction with adjuvant immunotherapy. Proposed benefits of CN include debulking of the primary tumour, which acts to stimulate the immune system to control residual disease, as well as removal of the source of potential new metastases [5] .
In the past two decades the von Hippel-Lindau (VHL) gene, a tumour suppressor gene, has been identified as an important step in renal carcinogenesis. A loss of VHL function, results in the accumulation of hypoxia-inducible factor (HIF), culminating in increased expression of pro-angiogenic growth factors, including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and pigment epithelial-derived factor (PEDF). These growth factors result in increased cell proliferation, survival and angiogenesis [6] . Inhibition of growth factor signalling pathways, by the introduction of targeted therapies, represents a novel strategy in the management of mRCC.
The efficacy of targeted therapies has been evaluated within numerous randomised phase III trials. Prolonged median survival and reduced toxicity when compared to immunotherapy have helped establish its central role in treatment protocols and international guidelines [7] [8] [9] [10] . However, whether a continuing surgical approach to mRCC management fits into this new treatment paradigm remains to be elucidated. We therefore present a review of the nonmedical treatments for mRCC and discuss the current status of CN within the targeted therapy era. response resulting in improved treatment outcomes when compared to immunotherapy, interleukin-2 and interferon a-2b (INF-a2b). Despite variations in efficacy and tolerability amongst targeted therapies, outcomes of randomised phase III trials reveal superior response rates, progression-free survival (PFS) and overall survival (OS), establishing its role as frontline in the systemic approach to mRCC [7] [8] [9] [10] . Sunitinib showed a marked therapeutic advantage over INF-a2b with a PFS of 26.4 months compared to 21.8 months [7] , supporting the recommendation by international guidelines as first-line in the management of mRCC. Sorafenib, a Raf kinase and VEGF inhibitor, revealed superior outcomes in OS when compared to placebo in patients with cytokine refractory mRCC (17.3 vs 14.8 months) [8] . Disappointingly bevacizumab, used in combination with INF-a2b, offered a non-significant marginal improvement in OS compared with INF-a2b alone with a median duration of 18.3 and 17.4 months, respectively [9] . Similarly, although temsirolimus showed superior OS compared to INF-a2b alone (10.9 vs 7.3 months) this was only observed on secondary analysis [10] .
Despite such shortfalls, overall targeted therapies demonstrate improved tolerability compared to immunotherapy, as well as a more favourable toxicity profile with reduced systemic symptoms such as fever, loss of appetite, malaise, and diarrhoea [7] [8] [9] [10] . In the clinical setting, this may improve health-related quality-of-life (HRQL) outcomes and prolong the initiation of second-line therapeutic interventions. Below is a summary of the existing major randomised control studies in mRCC (Table 1) [7, 9, 10, [12] [13] [14] [15] [16] [17] [18] .
Since their introduction, targeted therapies have largely superseded immunotherapy as frontline management of RCC within the metastatic setting. CN has historically been considered an integral part of the overall treatment strategy and it is important to be mindful that CN was a component of nearly all clinical trials. Consequently, the conferred survival benefit of targeted therapy must be appreciated within the context of a primary resected tumour [7] [8] [9] [10] . At present, although we know targeted therapy exhibits superior outcomes, we are unclear what impact and to what extent CN affects these outcomes. Furthermore, despite superior outcomes, response rates remain modest (10-15% to 40%) translating into marginal increases in 5-year survival rates [11] . Interestingly, interleukin-2 treatment was associated with a prolonged durable response in a small minority of patients; however; the associated morbidity and mortality was deemed unacceptable [19] . It is therefore important to not only consider primary endpoints, such as OS and PFS, but the risk of treatment and impact on HRQL [20] . These risks and outcomes often directly impact the patient's decision to continue further care. As a clinician being mindful of such factors is a key principal when counselling patients on their therapeutic options.
Role of CN in mRCC
The exact pathophysiological mechanisms explaining the rationale of CN in mRCC remain unclear. Primarily, CN is thought to result in a significant reduction in disease burden and development of new metastasis. Elucidation of renal cell carcinogenesis reveals it is largely an immunogenic tumour manipulating the function of the immune system, resulting in suppression of the anti-tumour effect exhibited by our defence mechanism [21] . During this process the primary tumour is thought to resist exogenous growth inhibitory signals, evade apoptosis and recruit angiogenic factor signals, whilst diverting the circulating immune system away from metastatic sites to reduce immunosurveillance. It has been proposed that CN removes these pro-angiogenic factors and relieves immunological suppression with a positive effect on residual disease [22] . Studies have also described CN to result in a low-grade systemic acidosis, acting to disrupt the tumour microenvironment and halting metastatic growth [23] .
Indications for CN include debulking tumour volume thereby reducing disease burden, as well as removal of the source of potential new metastases. Current evidence regards debulking a minimum of 75% of tumour volume as beneficial and is in fact recognised as an independent predictor of PFS [24, 25] . It may even result in improvement in patients' performance status affording them an opportunity to forego systemic therapy and withstand its associated toxicities. The regression of disease discussed earlier has been suggested by some authors as in fact a result of the removal of growth factors secreted by the tumour. Indeed, early reports supporting the role of CN noted spontaneous regression of metastatic disease in up to 1% of patients [26] . Further studies have suggested it may be a fortuitous event [27] , whilst others argue it may arise from the removal of growth factors secreted by the tumour [28] . Pragmatically the rarity of such cases precludes the identification of potential candidates for regression and should not be credited as a primary outcome [29] . Within a palliative setting, CN is often indicated for symptomatic control of intractable pain or haematuria and those of paraneoplastic syndromes including uncontrolled hypertension and refractory hypercalcaemia [30] . From a patient perspective, symptomatic alleviation may improve psychological well-being and increase acceptance/adherence to subsequent treatments.
CN in the Era of Cytokine Immunotherapy
Since the introduction of immunotherapy, CN has been considered an integral part of the multidisciplinary paradigm for the management of mRCC. This was based on favourable outcomes observed in two prospective randomised trials led by the European Organisation for the Research and Treatment of Cancer (EORTC) [12] and the Southwest Oncology Group (SWOG) [13] , which found prolonged PFS and median survival in nephrectomised patients. A pooled analysis of both trials noted these findings to be independent of clinical variables such as performance status, metastatic site and presence of absence of metastatic lesions, propelling the notion of performing CN in all surgically appropriate candidates [14] . However, limitations of these historic trials owing to significantly underpowered data and assignment of poorly matched patients, clouds the role of CN. Despite these shortcomings numerous, albeit retrospective studies, support the continued use of CN. In support of this a Cochrane-based analysis concluded that in appropriately selected surgical patients with mRCC, CN prior to immunotherapy provides the best survival strategy [31] .
CN in the Era of Targeted Therapy
The benefit derived from CN alongside newly developed targeted therapies remains unclear. Although current level 1 evidence is lacking, several non-randomised trials suggest a potential survival advantage. A recent meta-analysis of 11 non-randomised trials evaluating 39 953 patients with advanced RCC reported a 54% reduced risk of death in patients with combined CN and targeted therapy compared with targeted therapy alone [32] . One of the largest retrospective studies based on the Surveillance, Epidemiology and End Results (SEER) national database of 20 104 patients revealed an OS advantage of 19 vs 4 months in favour of patients who underwent CN [33] . Such improvements in survival benefit have been mirrored in studies varying from large national databases to large multicentre case series [32] .
Currently no study has prospectively validated the role of CN in conjunction with targeted therapies. Consequently, current international guidelines (European Association of Urology [EAU] and National Comprehensive Cancer Network [NCCN] ) recommending the use of CN are extrapolated from favourable outcomes demonstrated in the immunotherapy era [34, 35] . Interestingly, in the absence of level 1 evidence supporting CN, there has been a notable increasing trend in the use of targeted therapies whilst CN adoption has fallen. A study by Psutka et al. [36] revealed the annual rate of targeted therapy utilisation from 2004 to 2010 increased from 10% to 98.2%. Comparatively the utilisation of CN has halved from 30% to 15%, due to concerns it has the potential to delay systemic treatment with known clinical benefit. These concerns are born from a small series of retrospective data that found progression of disease, surgical morbidity and mortality precluded 77% of nephrectomised patients from receiving systemic therapy [37] . Although current evidence is based on small case series it highlights the importance of developing criteria to ascertain which patients would benefit from CN prior to systemic therapy. Below is a table describing the indications and disadvantages of CN in the targeted therapy era (Table 2 ).
Patient Selection in CN
Despite the lack of prospective randomised evidence for CN, in general, the identification of prognostic factors that allows risk stratification of patients prior to consideration of CN remains paramount. It allows selecting only those patients whom are likely to derive clinical benefit, whilst precluding those with an invariably poor prognosis from the complications of surgery and delay of systemic therapy [38] . Furthermore, it allows effective patient counselling providing clinicians with a tool to set realistic treatment expectations and goals.
Since the use of immunotherapy, several prognostic models have been developed with examples including the Memorial Sloan Kettering Cancer Centre (MSKCC) model. It defines pre-treatment predictors of survival in patients due to undergo immunotherapy. Predictors of poor outcomes include elevated lactate dehydrogenase, increased corrected calcium, low serum haemoglobin, low performance status score, and increased time from diagnosis to initiation of therapy. Patients are subsequently categorised into poor-, intermediate-or favourable-risk groups and have been shown to have significant differences in comparative median survival outcomes (OS: 4.9, 14 and 24 months, respectively) [39] . In the targeted therapy era, Heng et al. [40] have included elevated neutrophil and platelet count to the list of prognostic variables. The MSKCC prognostic score and its modification has recently been validated in large international dataset and is recommended in international guidelines to identify poorrisk patients for initiation of temsirolimus therapy [34, 35] .
Recently the eligibility criteria for CN patient selection has undergone re-evaluation, incorporating important determinants of adverse outcomes including performance status, number of metastatic sites, presence of nodal disease, and histological sub-type [41] . Whether these factors continue to remain relevant in the era of targeted therapies is debatable and requires further investigation. Currently the CARMENA trial (Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib) assessing CN alongside adjuvant sunitinib vs sunitinib monotherapy is underway, where it is hoped assessment of pre-defined clinical factors may address this ambiguity and aid the development of selection criteria specific to targeted therapy [15] .
Advances in CN
Over the last two decades advances in surgical techniques have significantly reduced postoperative morbidity rates associated with CN [42] . Minimally invasive surgery (MIS) techniques, such as laparoscopic CN (LCN), have grown in popularity since its initial description in 1991 by Clayman et al. [43] . Even more recently the use of robotic assistance has allowed MIS approaches to be used in increasingly complex tumours with even examples of management of tumours with inferior vena cava involvement [44] . Traditionally, open nephrectomy in the setting of mRCC was associated with significant morbidity, delaying or potentially precluding patients from receiving systemic immunotherapy [45] . In contrast, the application of a MIS approach can hasten recovery, shortening the interval prior to commencing systemic therapy.
Studies of LCN have consistently shown favourable outcomes including reduced postoperative pain, shorter hospital stay and a shorter period of rehabilitation when compared to open nephrectomy [46] . In a study from the National Cancer Institute, patients who underwent LCN had a shorter duration of recovery, expediting the administration of immunotherapy compared with those undergoing open CN [47] . Consistent with this, data from the Cleveland Clinic concluded that LCN resulted in a shorter hospital stay of 2.3 days compared to 6.1 days associated with an open Overall, it appears that fears of CN precluding patients from systemic therapy may be less relevant in the era of MIS. However, it should be highlighted surgical intervention for locally advanced tumours with renal vein, inferior vena cava or lymph node involvement may be beyond the scope of MIS [49] . Also, despite current evidence demonstrating superiority of MIS over open techniques, CN trials including the SWOG and EORTC have only utilised open approaches [12, 13] . Consequently, further large scale randomised trials powered to compare treatment outcomes of MIS with systemic therapy are warranted.
Timing of CN
Concerns over propagating metastatic disease progression by delaying targeted therapy after CN, has raised questions of utilising neoadjuvant therapy. Neoadjuvant targeted-therapy paradigms are common practice for many other malignancies including those of the gastrointestinal tract, thyroid, and breast [50] . Advantages of neoadjuvant targeted therapy primarily include down-staging/sizing of the primary tumour to facilitate resection and providing targeted patient selection by identifying poor responders who may not benefit from surgical intervention [51] .
A retrospective study comparing neoadjuvant with adjuvant sunitinib therapy found the former group was associated with superior disease-free survival and OS compared with the latter group. Furthermore, treatment responders who underwent CN had a significantly lower risk of death from mRCC compared to the adjuvant sunitinib group (9.1% and 58.8%, respectively) [52] . Less significantly, a small prospective trial evaluating treatment outcomes of neoadjuvant sunitinib found primary tumour down-staging correlated with long-term survival. Unfortunately, 68% of participants were non-responders and 36% of patients developed progressive metastatic disease. Although disappointing, this suggests disease progression could be used as a marker to identify individuals who are unlikely to benefit from CN but rather continued systemic treatment [53] . Such findings have previously been noted in the cytokine era; however, to be used as a predictive marker of prognosis, larger prospective studies are mandated. It is hoped prospective randomised data collated from the SURTIME trial (Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma), investigating the timing of CN with sunitinib, will shed more light on these potential selection criteria [16] . A further prospective phase II study led by Powles et al. [54] evaluating outcomes of neoadjuvant sunitinib, found OS was similar to standard treatment approaches (15.2 months). Despite these encouraging findings, PFS was notably short (6.3 months), which may be due in part to disease progression during the period of treatment interruption necessitated prior to CN. This period often lasts 4 weeks to prevent delayed wound healing and to optimise surgical recovery [55, 56] . However, it may also facilitate the development of sunitinib resistance restricting patients to second-line options [54] . Overall, this upfront approach allows for immediate initiation of treatment in patients with favourable-and intermediate-risk disease who will benefit from CN and in those with poor-risk disease who can avoid the morbid effects of surgery.
Disadvantages of delayed CN include concerns that targeted therapies may potentiate surgical morbidity by targeting pro-angiogenic properties associated with inhibiting VEGF and other signalling pathways [57] . This can lead to impaired microvasculature increasing the likelihood of postoperative bleeding and thromboembolic events. Furthermore, these pathways play a vital role in tissue integrity with subsequent disruption leading to an increase in impaired wound healing rates and incisional hernia incidence. Withholding systemic therapy for an appropriate duration before or after surgery may help preserve microvasculature, tissue integrity, and reduce adverse effects [58] . At present, there is limited data on the recommended duration of delay, as well as the safety profile of neoadjuvant targeted therapy and delayed CN as a combined treatment strategy. Promisingly, recent prospective data evaluating neoadjuvant sunitinib revealed this treatment paradigm to be generally safe and well tolerated with minor complications mirroring the morbidity of patients undergoing initial surgical resection [55] . Overall, current evidence supports the integration of delayed CN and targeted therapies in appropriately selected patients. Importantly, prognostic factors and performance status play a significant role in determining which patients are most likely to benefit from this treatment paradigm.
Role of Metastasectomy in mRCC
Recently, small trials have shown a positive impact of CN alongside metastasectomy in selected patients with lowvolume mRCC, regarding survival outcomes. Eggener et al. [59] demonstrated surgical resection of recurrent metastatic foci in 44 patients was clinically beneficial across risk groups as categorised by the MSKCC model. Consistent with these findings Alt et al. [60] found a significant three-fold increase risk of death in patients who failed to undergo complete metastasectomy, suggesting complete resection of macroscopic metastases should be considered in surgically appropriate candidates. Findings from a systematic review identified eight studies comparing complete metastasectomy, incomplete metastasectomy or no metastasectomy. Assessment of OS unequivocally favoured complete metastasectomy compared to no metastasectomy (40.8 vs 14.8 months) [61] . Although current evidence favours metastasectomy (in appropriately 324 © 2017 The Authors BJU International © 2017 BJU International selected cases), the benefit of targeted therapy use after metastasectomy requires further evaluation.
Role of Nephron-Sparing Surgery in mRCC
Nephron-Sparing Surgery has recently been evaluated in the management of mRCC for individuals where preservation of renal function is paramount. A retrospective study, evaluating matched patients undergoing NSS compared to radical nephrectomy (RN) found comparable survival outcomes [62] . However, due to the small sample size (54 cases) deriving clinically meaningful outcomes is difficult. A more recent study found NSS was associated with superior cancer-specific survival rates at 1, 3 and 5 years compared with RN (81%, 49% and 49% compared with 51%, 21% and 13%) [63] . This advantage could partly be explained by the preservation of renal function in NSS, whereas RN can lead to deteriorating renal function and subsequent complications associated with the development of chronic kidney disease. However, due to the retrospective nature of the study it is likely selection bias may have also contributed to these encouraging findings. In future it will be interesting to assess how the relationship between targeted therapies and the combination of surgical interventions including metastasectomy alongside CN, CN alone or CN vs NSS compare in response rates, PFS and OS outcomes. Notably each surgical intervention has its own eligibility criteria for patient selection that involves incorporating varying prognostic factors relevant to each modality. This in turn could be affected when combined with targeted therapy.
Role of Combined Targeted Therapy in mRCC
The role of combined targeted treatment allows the targeting of separate pathways involved in renal cell carcinogenesis, which has been postulated to maximise treatment outcomes. The potential of synergistic anti-tumour effects with combined therapy has been evaluated in a phase I study assessing sunitinib combined with tremelimumab an anticytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody within the metastatic setting. Of 21 patients, nine achieved a partial tumour response; however, it resulted in unacceptable toxic outcomes including acute renal failure and will not be further evaluated [64] . A larger prospective study of 63 patients treated with bevacizumab and erlotinib, targeting EGF revealed 25% had positive treatment responses. The authors proposed the efficacy of combined treatment was superior to either drug alone, owing to targeting of multiple signalling pathways [65] . Unfortunately, development of this study with the addition of imatinib to bevacizumab/erlotinib proved to increase grade 3/4 toxicities including diarrhoea, rash, and fatigue [66] . Vaccines in conjunction with targeted therapies are also being explored. Findings from a phase II study evaluating a dendritic cell-based vaccine AGS-003 with sunitinib compared with sunitinib monotherapy showed superior PFS (11.9 vs 8 months, respectively). Importantly no added toxicity was observed [67] .
Overall, the potential benefit of combined treatment strategies with complementary mechanism of action support the use of targeted therapies in combination with immunotherapies, vaccines, and T-cell modulating agents [68] . Although, emerging evidence of early phase clinical trials appear promising, clinicians must be mindful of the potential toxicity of combined regimens.
Current Guidelines
EAU guidelines support a multimodality approach to the treatment of mRCC including CN, metastasectomy and systemic treatment with targeted therapies [34] . Surgically, CN is recommended in appropriately selected patients. This is primarily based on meta-analysis of the EORTC and SWOG trials; however, as mentioned previously, such data precedes targeted therapy and is in the context of immunotherapy [14] . Metastasectomy is recommended as the most appropriate local treatment for most sites. This is based on retrospective data supporting the benefit of complete metastasectomy in terms of OS, cancer-specific survival and delay of systemic therapy. Sunitinib and pazopanib are recommended as first-line systemic therapy for clear cell mRCC. Bevacizumab is recommended for those with favourable-or intermediaterisk, whereas temsirolimus is reserved for poor-risk groups [34] .
The NCCN guidelines used in the USA recommend CN before systemic therapy based on patient selection criteria including lung-only metastasis, good prognostic factors, and good performance status [35] . These recommendations, although not supported by level 1 evidence, are based on data from the International mRCC database consortium [69] . Following this, similar to the EAU guidelines, sunitinib, bevacizumab and pazopanib are recommended as first-line treatments with temsirolimus reserved as first-line in poorrisk patients. Predictors of poor prognosis are based on the MSKCC prognostic model and defined as those with more than three predictors of short survival.
Future Directions -Checkpoint Immune Inhibitors
Despite modest improved outcomes provided by targeted therapies, resistance eventually develops in most cases, necessitating alternative treatment strategies. Immunotherapy has re-emerged as a potential strategy by the introduction of checkpoint inhibitors targeting the anti-tumour immune response of the host [70] .
The interaction between programmed death-1 (PD-1) present on T-cells and its ligand, PD-L1 present on antigen presenting cells and tumour cells, acts to induce T-cell tolerance and avoid immune destruction [71] . Monoclonal antibodies disrupt this interaction acting as inhibitors of this immune checkpoint, translating to improved therapeutic outcomes [72] . A monoclonal IgG4 antibody specific for PD-1, known as nivolumab, has recently been trailed against everolimus in the Checkmate 025 trial. Both OS and PFS were more favourable in the nivolumab arm compared to everolimus arm (OS: 25 and 19.6 months; PFS: 4.6 and 4.4 months, respectively.) Furthermore, the rate of grade 3/4 toxicities were lower with nivolumab compared to everolimus [73] . These initial findings have paved the way for combined treatment strategies with immune checkpoint inhibitors. Currently numerous phase III studies comparing combined immunotherapy with first-line targeted therapy, sunitinib and bevacizumab are underway [74, 75] . It is hoped that outcomes of these pending trials translates into clinically meaningful benefits for patients, forming an additional arm in multimodality approach to mRCC. Below is a summary of randomised trials evaluating neoadjuvant TKI in mRCC (Table 3 ) [52] [53] [54] .
Conclusion
Cytoreductive nephrectomy alongside adjuvant cytokine immunotherapy is a well-established treatment protocol in the management of mRCC, demonstrating independent significant survival advantage when compared to immunotherapy alone. Since then, the introduction of targeted therapies have resulted in modest improvements in patient survival when compared to cytokine immunotherapy. Advances in surgical techniques and procedures, coupled with manipulation of targeted therapy dosing regimens and combined therapeutic strategies have further optimised treatment outcomes and prolonged OS in the research setting. However, in the clinical setting response rates remain modest and PFS temporary, translating into marginal improvements in 5-year mortality rates. With continuing innovation, the role of CN within the metastatic setting will no doubt change in the foreseeable future. Whether CN continues to play a role in mRCC management in the targeted therapy era or whether it is superseded by combined systemic therapeutic strategies alone remains to be evaluated in randomised prospective trials. Questions will likely arise on the appropriate timing of CN and which prognostic factors can be used to identify surgically appropriate candidates. Current evidence based on nonrandomised retrospective trials is promising; however, outcomes of the CARMENA and SURTIME trials are eagerly anticipated to advance this evidence base. Until then, based on evidence of the beneficial role of CN alongside immunotherapy, CN should not be abandoned but still be considered as a viable therapeutic strategy in the multimodal approach to mRCC in carefully selected patients.
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